KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
JP3240600001
LEI:
Country:
Japan
Address:
松本市芳野19番48号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company strategically focuses its research and development efforts on specific therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its business model integrates in-house drug discovery with strategic partnerships, such as in-licensing and out-licensing agreements, to build a robust product pipeline. Kissei's portfolio comprises both specialty and generic drugs, aiming to address unmet medical needs and contribute to the health of people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:34
Interim Report
確認書
Japanese 8.9 KB
2025-11-10 08:33
Interim Report
半期報告書-第81期(2025/04/01-2026/03/31)
Japanese 236.4 KB
2025-06-27 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 06:01
Governance Information
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
Annual Report
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
Major Shareholding Notification
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 05:00
Interim Report
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
Governance Information
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
Registration Form
確認書
Japanese 9.0 KB
2024-06-25 06:00
Registration Form
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KISSEI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.